NCT04133480View on ClinicalTrials.gov

Investigation of Cognitive Outcomes With Cannabidiol Oral Solution

PHASE4WithdrawnINTERVENTIONAL
0
Timeline

Start Date

October 31, 2020

Primary Completion Date

December 31, 2021

Study Completion Date

December 31, 2021

Conditions
Lennox-Gastaut Syndrome
Interventions
DRUG

GWP42003-P

oral solution of 100 milligrams per milliliter (mg/mL) cannabidiol (CBD)

Sponsors
All Listed Sponsors
lead

Jazz Pharmaceuticals

INDUSTRY